MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Kinase Inhibitors

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal

Carcinogenesis 2018 April [Link] Schelch K et.al Abstract Malignant pleural mesothelioma (MPM), an aggressive malignancy affecting pleural surfaces, occurs in three main histological subtypes. The epithelioid and sarcomatoid subtypes are characterized by cuboid and fibroblastoid cells, respectively. The biphasic subtype contains a mixture of both. The sarcomatoid subtype expresses markers of epithelial-mesenchymal transition (EMT) and […]

Comments Off on FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal

Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma

Journal of Thoracic Oncology 2017 December [Epub ahead of print] [Link] Tsao AS et.al. Abstract Window-of-opportunity trials in malignant pleural mesothelioma (MPM) are challenging but can yield important translational information about a novel agent. We treated MPM patients (n=24) with 4 weeks of oral dasatinib followed by surgery with or without radiotherapy and then an […]

Comments Off on Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma

Focal Adhesion Kinase a Potential Therapeutic Target for Pancreatic Cancer and Malignant Pleural Mesothelioma

Cancer Biology & Therapy 2018 January 5 [Epub ahead of print] [Link] Kanteti R, et. al. Abstract The non-receptor cytoplasmic tyrosine kinase, Focal Adhesion Kinase (FAK) is known to play a key role in a variety of normal and cancer cellular functions such as survival, proliferation, migration and invasion. It is highly active and overexpressed […]

Comments Off on Focal Adhesion Kinase a Potential Therapeutic Target for Pancreatic Cancer and Malignant Pleural Mesothelioma

Modulation of reactive oxygen species via ERK and STAT3 dependent signalling are involved in the response of mesothelioma cells to exemestane

Free Radical Biology and Medicine 2017 December [Epub ahead of print] [Link] Nuvoli B, Camera E, Mastrofrancesco A, Briganti S, Galati R Abstract Pleural mesothelioma is a deadly form of cancer. The prognosis is extremely poor due to the limited treatment modalities. Uptake of asbestos fibres, the leading cause of mesothelioma, lead to the accumulation […]

Comments Off on Modulation of reactive oxygen species via ERK and STAT3 dependent signalling are involved in the response of mesothelioma cells to exemestane

Application of 3D Mass Spectrometry Imaging to TKIs

Clinical Pharmacology and Therapeutics 2017 November [Link] Morosi L, Giordano S, Falcetta F, Frapolli R, Licandro SA, Matteo C, Zucchetti M, Ubezio P, Erba E, Visentin S, D’Incalci M, Davoli E Abstract Mass spectrometry imaging (MSI) allows visualization of endogenous and exogenous compound in tissue sections based on its molecular mass. The 3D reconstruction by […]

Comments Off on Application of 3D Mass Spectrometry Imaging to TKIs

Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma

JAMA Oncology 2017 September [Epub ahead of print] [Link] Hung YP, Dong F, Watkins JC, Nardi V, Bueno R, Dal Cin P, Godleski JJ, Crum CP, Chirieac LR Abstract IMPORTANCE: Malignant peritoneal mesothelioma is a rare, aggressive tumor arising from the peritoneal lining, induced by asbestos, therapeutic radiation, or germline mutations. Nevertheless, the molecular features […]

Comments Off on Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma

Novel systemic therapy against malignant pleural mesothelioma

Translational Lung Cancer Research 2017 June [Link] Mancuso MR, Neal JW Abstract Malignant pleural mesothelioma is an aggressive tumor of the pleura with an overall poor prognosis. Even with surgical resection, for which only a subset of patients are eligible, long term disease free survival is rare. Standard first-line systemic treatment consists of a platinum […]

Comments Off on Novel systemic therapy against malignant pleural mesothelioma

Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers

Discovery Medicine 2017 May [Link Rimkus T, Sirkisoon S, Harrison A, Lo HW Abstract Tumor suppressor candidate 2 (TUSC2, also known as FUS1) was identified in 2000 as a candidate tumor suppressor gene located in a region on chromosome 3p21.3 that is homozygously deleted in some lung and breast cancers. The deletion is rare in […]

Comments Off on Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers

JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

Current Cancer Drug Targets 2017 June 23 [Epub ahead of print] [Link] Zanellato I, Colangelo D, Osella D Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated tumor with poor prognosis and few therapeutic options. JQ1, a selective antagonist of BRD4, modulates transcription of oncogenes, including MPM chemoresistance-associated c-Myc and Fra-1. We investigated if JQ1 could […]

Comments Off on JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

Connexin 43 enhances Bax activation via JNK activation in sunitinib-induced apoptosis in mesothelioma cells

Journal of Pharmacological Sciences 2017 May [Epub ahead of print] [Link] Uzu M, Sato H, Shimizu A, Shibata Y, Ueno K, Hisaka A Abstract The constituent protein of gap junctions, connexin (Cx), interacts with various proteins via its C-terminus region, including kinases, cell-adhesion proteins, and a pro-apoptotic protein, Bax. This molecular interaction may affect expression […]

Comments Off on Connexin 43 enhances Bax activation via JNK activation in sunitinib-induced apoptosis in mesothelioma cells